PharmQuest and e.Lilly to collaborate to accelerate product development processes
The investment gives Lilly access to the PharmQuest flagship product, eSWAT (electronic Seamless Workflow Automation Toolbox), a framework that configures and integrates legacy systems and other software tools over a company's Intranet. In addition, PharmQuest has acquired two proprietary systems from Lilly and will develop these systems as part of PharmQuest's DrugSmarts product line, knowledge management solutions for the drug development process.
"Lilly has established one of the most extensive discovery and development efforts within the biotech and pharmaceutical community," said Boyd Poulsen, Chairman of PharmQuest. "We recognize Lilly's capacity to generate a significant number of high-quality therapeutic targets and value their confidence in our technology to support development of these leads into products that are safe and efficacious - better and faster."
PharmQuest's technologies and services enable drug developers in the biotechnology and pharmaceutical industry to access, manage and streamline relevant decision-making information to improve the success rate and speed of drugs to market. In its first year of operation PharmQuest has established relationship wit 3 large pharmaceutical companies.